CHI3L1 and neoplasm: This intra- and inter-tumor heterogeneity in glioblastoma complicates the analysis of potential correlations between molecular subtype and biomarkers like YKL-40 [41] and a more advanced subtyping could strengthen the use of YKL-40 as a biomarker for bevacizumab response.